Search

Your search keyword '"Azodi, M"' showing total 604 results

Search Constraints

Start Over You searched for: Author "Azodi, M" Remove constraint Author: "Azodi, M"
604 results on '"Azodi, M"'

Search Results

1. Modeling of karst and alluvial springs discharge in the central Alborz highlands and on the Caspian southern coasts

6. Two-Port Robotic Laparoscopic Hysterectomy

9. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

12. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

13. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

16. Patient experience with medical marijuana in women with gynecologic malignancies: A single-institution survey-based study

17. The PARP inhibitor niraparib demonstrates preclinical activity against HRD-deficient carcinosarcomas

18. Chemotherapy choice and impact on survival of patients with carcinosarcoma of the ovary: A retrospective review

19. Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis

20. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab-govitecan

21. Safety and Efficacy Results of Retreatment With a PARP Inhibitor Monotherapy in Late-Line Recurrent Ovarian Cancer: Results From a Subset of the QUADRA Trial

27. Sacituzumab govitecan (IMMU-132) in uterine serous carcinoma

29. The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in epithelial ovarian carcinoma overexpressing HER2.

36. QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset

37. Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancers

40. Aqueous Extract of Lavender Angustifolia Inhibits Lymphocytes Proliferation of Hodgkin's Lymphoma Patients

41. Effects of intermittent feeding on compensatory growth, feed intake and body composition in Asian sea bass (Lates calcarifer)

48. Neratinib shows efficacy in the treatment of HER2/neu amplified epithelial ovarian carcinoma in vitro and in vivo

50. Effects of dietary probiotic (Lactobacillus plantarum) on body composition, serum biochemical parameters and liver enzymes of Asian sea bass (Lates calcalifer, Bloch 1790)

Catalog

Books, media, physical & digital resources